Alvimopan
As of the edition of 20 October 2026, Alvimopan is a small molecule: marketed, first approved in 2008 (US); acts on OPRM1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Entereg
- First approved
- 20 May 2008 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Merck & Co.
- Registered trials
- 21, 6 stopped early
- Disease areas
- Digestive system; Cancer; Pregnancy and women's health; Urinary and reproductive; Chemically induced; Hormones
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Alvimopan.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OPRM1 | Mu-type opioid receptor | P35372 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 0 | 1 |
| Phase 2 | 4 | 2 | 0 | 2 |
| Phase 3 | 10 | 8 | 1 | 1 |
| Phase 4 | 4 | 2 | 0 | 2 |
| All trials | 21 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Acquired holder and Lead sponsor of trials | 2001 to now |